MedPage Today on MSN
Myasthenia Gravis Complement Inhibitor Meets Primary Endpoint in Phase III Trial
SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...
MedPage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...
DelveInsight’s Complement 3 Glomerulopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of ...
When it comes to the English language, I'm confident no one meant to confuse us. There wasn't a panel of mean English teachers who sat around a table, finding ways to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback